The effect of physostigmine and Neostigmine on the concentration of glycogen in the liver of the rat.
D000315:Adrenalectomy; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D002219:Carbamates / Q000494:pharmacology; D004837:Epinephrine / Q000494:pharmacology; D006003:Glycogen / Q000378:metabolism; D006145:Guanethidine / Q000494:pharmacology; D006584:Hexamethonium Compounds / Q000494:pharmacology; D008112:Liver Glycogen / Q000378:metabolism*; D008297:Male; D009206:Myocardium / Q000378:metabolism; D009388:Neostigmine / Q000494:pharmacology*; D010646:Phentolamine / Q000494:pharmacology; D010830:Physostigmine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D012110:Reserpine / Q000494:pharmacology; D013564:Sympathetic Nervous System / Q000187:drug effects
D001786:Blood Glucose; D002219:Carbamates; D006584:Hexamethonium Compounds; D008112:Liver Glycogen; D009388:Neostigmine; D001285:Atropine; D012110:Reserpine; D006003:Glycogen; D010830:Physostigmine; D011433:Propranolol; D004837:Epinephrine; D010646:Phentolamine; D006145:Guanethidine